News

September 22nd 2022

The faces behind the CARE work-packages – WP6

The faces behind the CARE work-packages - WP6 CARE (Corona Accelerated R&D in Europe) is the largest European research initiative addressing the challenges of COVID-19. It is no surprise that it is designed in a comprehensive, yet agile, structure to fulfill the 37 partners’ shared key goals: (1) to identify therapeutics for the current pandemic, (2) to identify antiviral therapies for future outbreaks and (3) [...]
Read more
August 2nd 2022

The faces behind the CARE work-packages – WP5

The faces behind the CARE work-packages - WP5 CARE (Corona Accelerated R&D in Europe) is the largest European research initiative addressing the challenges of COVID-19. It is no surprise that it is designed in a comprehensive, yet agile, structure to fulfill the 37 partners’ shared key goals: (1) to identify therapeutics for the current pandemic, (2) to identify antiviral therapies for future outbreaks and (3) [...]
Read more
July 26th 2022

The faces behind the CARE work-packages – WP4

The faces behind the CARE work-packages - WP4 CARE (Corona Accelerated R&D in Europe) is the largest European research initiative addressing the challenges of COVID-19. It is no surprise that it is designed in a comprehensive, yet agile, structure to fulfill the 37 partners’ shared key goals: (1) to identify therapeutics for the current pandemic, (2) to identify antiviral therapies for future outbreaks and (3) [...]
Read more
July 19th 2022

Published in eBioMedicine: Design, immunogenicity, and efficacy of a pan-sarbecovirus dendritic-cell targeting vaccine

Published in eBioMedicine: Design, immunogenicity, and efficacy of a pan-sarbecovirus dendritic-cell targeting vaccine The CARE partner Centre Institut National De La Santé Et De La Recherche Médicale – Vaccine Reserch Institute (INSERM-VRI) published a paper reporting on the design and testing of a protein subunit vaccine CD40.CoV2. The immunogenicity and antiviral efficacy of the vaccine [...]
Read more
July 12th 2022

Published in JAMA Oncology: Humoral Responses Against Variants of Concern by COVID-19 mRNA Vaccines in Immunocompromised Patients

Published in JAMA Oncology: Humoral Responses Against Variants of Concern by COVID-19 mRNA Vaccines in Immunocompromised Patients The CARE partner Centre Hospitalier Universitaire Vaudois (CHUV) in collaboration with Lausanne University Hospital published a paper reporting on the durability of neutralizing antibody responses elicited by messenger RNA vaccines BNT162b2 (Pfizer-BioNTech) or mRNA-1273 (Moderna) against the SARS-CoV-2 [...]
Read more
July 7th 2022

Published in MDPI: Synthesis, Structure-Activity Relationships, and Antiviral Profiling of 1-Heteroaryl-2-Alkoxyphenyl Analogs as Inhibitors of SARS-CoV-2 Replication

Published in MDPI: Synthesis, Structure-Activity Relationships, and Antiviral Profiling of 1-Heteroaryl-2-Alkoxyphenyl Analogs as Inhibitors of SARS-CoV-2 Replication The CARE partners Katholieke Universiteit Leuven (KUL), Universiteit Utrecht (UU), University Of Dundee (UNIVDUN), Universitaet Zu Luebeck (UZL) in collaboration with a number of other organisations published a paper reporting on the conduct of a high-throughput screening of a 160 K compound library against SARS-CoV-2, yielding [...]
Read more
July 5th 2022

Published in CellPress iScience: Computed Tomography and [18 F]-FDG PET imaging provide additional readouts for COVID-19 pathogenesis and therapies evaluation in non-human primates

Published in CellPress iScience: Computed Tomography and [18 F]-FDG PET imaging provide additional readouts for COVID-19 pathogenesis and therapies evaluation in non-human primates  The CARE partners Institut National De La Santé Et De La Recherche Médicale – Vaccine Research Institute (INSERM-VRI) and Commissariat À L'énergie Atomique Et Aux Énergies Alternatives (CEA) published a paper reporting [...]
Read more
June 30th 2022

CARE 2nd Annual meeting

CARE 2nd Annual meeting CARE 2nd Annual meeting was successfully held in Paris on 9-10 June 2022, in presence of CARE Scientific and Ethics Advisory Board and IHI Project Officer.  Around 60 people attended in person and 50 remotely to listen to and to discuss the project progress, achievements and next steps.
Read more
May 31st 2022

CARE paper published in Antiviral Research: Insight on the activity of Remdesivir, Molnupiravir and Nirmatrelvir on SARS-CoV-2 variants of concern

CARE paper published in Antiviral Research: Insight on the activity of Remdesivir, Molnupiravir and Nirmatrelvir on SARS-CoV-2 variants of concern The CARE partner KU Leuven, in collaboration with University Hospitals Leuven evaluated the susceptibility of SARS-CoV-2 variants   to Remdesivir, Molnupiravir and Nirmatrelvir. The three molecules have in vitro antiviral activities against the ancestral virus as [...]
Read more
May 24th 2022

CARE paper published in Journal of Medical Virology: Development and optimization of a high-throughput screening assay for in vitro anti-SARS-CoV-2 activity

CARE paper published in Journal of Medical Virology: Development and optimization of a high-throughput screening assay for in vitro anti-SARS-CoV-2 activity The CARE partners KU Leuven and Janssen Pharmaceutica NV, in collaboration with The Institute of Medical Virology published a paper reporting on the outcomes from screening a library of antiviral compounds to assess effectiveness [...]
Read more
February 24th 2022

White paper published: High throughput cryo-electron microscopy epitope mapping of SARS-CoV-2 spike protein antibodies

High throughput cryo-electron microscopy epitope mapping of SARS-CoV-2 spike protein antibodies The CARE partners Takeda and Utrecht University, in collaboration with Thermo Fisher Scientific, published a white paper demonstrating how cryo-electron microscopy can be used as tool for high-throughput epitope mapping of antibodies that block SARS-CoV-2 virus entry. One of the main concerns of the [...]
Read more
February 21st 2022

Published in Nature Communications: Mechanism of AT-527 presents as a promising research avenue against COVID-19

Published in Nature Communications: Mechanism of AT-527 presents as a promising research avenue against COVID-19 A research group including the CARE partner Aix-Marseille University investigated the guanosine analogue AT-527 (Bemnifobuvir) using high-resolution cryo-electromicroscopy. Once in cells, AT-527 is converted into AT-9010that presumably has a dual mechanism of action (1) at the level of the viral [...]
Read more
February 14th 2022

The faces behind the CARE work-packages – WP3

The faces behind the CARE work-packages - WP3 CARE (Corona Accelerated R&D in Europe) is the largest European research initiative addressing the challenges of COVID-19. It is no surprise that it is designed in a comprehensive, yet agile, structure to fulfill the 37 partners’ shared key goals: (1) to identify therapeutics for the current pandemic, (2) to identify antiviral therapies for future outbreaks and (3) [...]
Read more
January 10th 2022

The faces behind the CARE work-packages – WP2

The faces behind the CARE work-packages - WP2 CARE (Corona Accelerated R&D in Europe) is the largest European research initiative addressing the challenges of COVID-19. It is no surprise that it is designed in a comprehensive, yet agile, structure to fulfill the 37 partners’ shared key goals: (1) to identify therapeutics for the current pandemic, (2) to identify antiviral therapies for future outbreaks and (3) [...]
Read more
December 13th 2021

The faces behind the CARE work-packages – WP1

The faces behind the CARE work-packages - WP1 CARE (Corona Accelerated R&D in Europe) is the largest European research initiative addressing the challenges of COVID-19. It is no surprise that it is designed in a comprehensive, yet agile, structure to fulfill the 37 partners’ shared key goals: (1) to identify therapeutics for the current pandemic, (2) to identify antiviral therapies for future outbreaks and (3) [...]
Read more
December 9th 2021

CARE paper published in JCIM: Modeling of protein-small molecule complexes with HADDOCK

CARE paper published in JCIM: Modeling of protein-small molecule complexes with HADDOCK CARE partners of the University of Utrecht studied the interactions between compounds and protein receptors using a new protocol in HADDOCK (High Ambiguity Driven DOCKing). Compound-protein interactions are a crucial task in drug discovery and HADDOCK is an integrative modeling platform which incorporates [...]
Read more
December 6th 2021

CARE paper published in Journal of Virology: New insights for assessment of SARS-CoV-2 infection estimates and (vaccine-induced) antibody durability response

CARE paper published in Journal of Virology: New insights for assessment of SARS-CoV-2 infection estimates and (vaccine-induced) antibody durability response  CARE researchers have determined SARS-CoV-2-specific antibody responses to different proteins (trimeric spike protein, monomeric spike protein and nucleocapsid protein) in sera of people infected with COVID-19 in acute-infection and post-infection phases. The results suggest that [...]
Read more
December 2nd 2021

CARE paper published in Science Translational Medicine: New cell-free assay

CARE paper published in Science Translational Medicine: New cell-free assay  A CARE research team developed a cell-free assay to quantify neutralizing antibody responses. Neutralizing antibody responses to SARS-CoV-2 are usually assessed using cell-based assays requiring live virus. These assays are time-consuming and necessitate additional biosafety precautions, thus limiting their clinical use. The new cell-free assay [...]
Read more
November 30th 2021

CARE paper published in Circulation: Mechanisms of SARS-CoV-2 with regards to endothelial cells

CARE paper published in Circulation: Mechanisms of SARS-CoV-2 with regards to endothelial cells The CARE scientists investigated if the coronavirus infects and damages endothelial cells directly by viral infection or indirectly via neighborhood effects, circulating mediators and immune mechanisms. Endothelial cells build a cell layer that lines blood vessels and regulates exchanges between the blood [...]
Read more
November 26th 2021

CARE paper published in iScience: CD177 is associated with coronavirus disease 2019 severity and death

CARE paper published in iScience: CD177 is associated with coronavirus disease severity  In an effort to increase the understanding of SARS-CoV-2, CARE researchers found that the activation of a type of white blood cells called neutrophils could be linked to the overexpression of a protein encoded by the CD177 gene. They concluded that CD177 is [...]
Read more
November 22nd 2021

CARE paper published in Nature: HCQ use against SARS-CoV-2 infection

CARE paper published in Nature: HCQ use against SARS-CoV-2 infection CARE scientists demonstrated that there is no definitive evidence that Hydroxychloroquine (HCQ), whether alone or in combination with azithromycin, is effective for treating COVID-19. The investigation was part of CARE’s efforts to evaluate the efficacy of repurposed drugs. To learn more, read the paper in [...]
Read more
October 8th 2021

Repurposing efforts concluded

Repurposing efforts conducted The partners of the CARE consortium conducted a high throughput screening (HTS), or testing, of approximately 20,000 approved or clinically validated compounds as part of its emergency response track (pillar 1 of the research programme). The CARE research teams identified several single digit µM compounds. However, none of these were deemed beneficial [...]
Read more
October 4th 2021

CARE scientists identified a SARS-CoV-2 neutralizing antibody with activity against all known variants of concern

CARE scientists identified a SARS-CoV-2 neutralizing antibody with activity against all known variants of concern One of CARE’s approach to develop therapeutics to address the COVID-19 pandemic is the discovery of virus neutralizing antibodies. With this goal, the CARE partner Centre Hospitalier Universitaire Vaudois screened B cells from COVID-19 donors and identifyed P5C3, a highly [...]
Read more
May 31st 2021

One Year of CARE Against COVID-19

One Year of CARE Against COVID-19 / Interview Part 3 / On March 11, 2020 the novel coronavirus outbreak has been declared a pandemic. To combat the virus, multiple approaches are needed including therapeutic options that help those who are infected and those who are not able to be vaccinated or do not develop a strong immune response. In addition, [...]
Read more
May 17th 2021

One Year of CARE Against COVID-19

One Year of CARE Against COVID-19 / Interview Part 2 / On March 11, 2020 the novel coronavirus outbreak has been declared a pandemic. To combat the virus, multiple approaches are needed including therapeutic options that help those who are infected and those who are not able to be vaccinated or do not develop a strong immune response. In addition, [...]
Read more
May 3rd 2021

One Year of CARE Against COVID-19

One Year of CARE Against COVID-19 / Interview Part 1 / On March 11, 2020 the novel coronavirus outbreak has been declared a pandemic. To combat the virus, multiple approaches are needed including therapeutic options that help those who are infected and those who are not able to be vaccinated or do not develop a strong immune response. In addition, [...]
Read more
April 2nd 2021

Survey on GDPR and eConsent during the COVID-19 pandemic

Survey on Data protection and eConsent during the COVID-19 pandemic The team of task 8.3 Ethical, legal, and societal issues (ELSI) on broad spectrum anti-coronavirus therapeutics development is pleased to invite you to take part in an online survey to share your experience on key challenges related to compliance with the EU General Data Protection [...]
Read more
October 6th 2020

Mention of CARE in Le Monde

Mention of the CARE project in Le Monde newspaper The CARE project and a few of its coordinator and principal investigators (Yves Lévy, Bruno Canard, Johan Neyts) have been mentioned in an article published on Nature.com on October 6th 2021.  Read the article
Read more
September 21st 2020

EMA – ITF collaboration

Innovation Task Force Leaders of the IMI CARE and SCORE consortia joined an Innovation Task Force (ITF) meeting with the European Medicines Agency (EMA) on September 21, 2020. Establishing an exchange between the consortia and the EMA at an early stage, the participants focused in this preparatory discussion on scientific and regulatory topics relevant to the development [...]
Read more
August 31st 2020

IMI Press release

CARE embarks on an unprecedented mission to get ready for coming COVID-19 waves and new coronavirus outbreaks. The world needs to prepare for a future wherein waves of COVID-19 and other coronavirus outbreaks become part of the landscape. Apart from studying the potential of existing drugs to treat COVID-19 in the short-term, the CARE consortium [...]
Read more
August 18th 2020

CARE Press release

Launch of CARE Press release “Europe’s Largest Initiative Launches to Accelerate Therapy Development for COVID-19 and Future Coronavirus Threats” Read more Leaders of the IMI CARE and SCORE consortia joined an Innovation Task Force (ITF) meeting with the European Medicines Agency (EMA) on September 21, 2020. Establishing an exchange between the consortia and the EMA at an [...]
Read more
July 7th 2020

CARE Kick-off meeting week

Virtual meeting week A fruitful week to gather the Consortium partners and discuss the Work Packages. The coordinators reiterated that the overarching vision of CARE is to develop appropriate therapeutic agents to address the immediate patient need and to prepare use in any future outbreaks for any type of coronaviruses. The aim of this ambitious [...]
Read more
April 1st 2020

Start of the CARE project

The CARE project officially started on April 1st 2020. IMI launched the IMI-2 Call 21 on COVID on March 3, 2020, and the project was submitted on March 31, 2020. The results were known on May 11, 2020, and CARE was selected together with 7 other consortia. The CARE project started retrospectively on April 1, [...]
Read more